BELLUS Health Inc. (NASDAQ:BLU – Get Rating) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 15,530,000 shares, an increase of 21.9% from the June 30th total of 12,740,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 13.9 days.
Analyst Ratings Changes
Separately, Royal Bank of Canada upped their price target on shares of BELLUS Health from $14.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, BELLUS Health currently has a consensus rating of “Buy” and a consensus price target of $18.25.
Institutional Investors Weigh In On BELLUS Health
A number of hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank increased its stake in BELLUS Health by 35,900.0% in the 1st quarter. Toronto Dominion Bank now owns 3,600 shares of the company’s stock worth $25,000 after acquiring an additional 3,590 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of BELLUS Health in the first quarter valued at $27,000. ProShare Advisors LLC bought a new stake in BELLUS Health in the fourth quarter worth $89,000. Belvedere Trading LLC purchased a new stake in BELLUS Health during the second quarter valued at $96,000. Finally, Cibc World Market Inc. bought a new position in BELLUS Health during the first quarter valued at $98,000. 85.41% of the stock is currently owned by hedge funds and other institutional investors.
BELLUS Health Price Performance
BELLUS Health (NASDAQ:BLU – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. BELLUS Health had a negative net margin of 436,406.25% and a negative return on equity of 35.61%. On average, sell-side analysts anticipate that BELLUS Health will post -0.77 earnings per share for the current year.
About BELLUS Health
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
- Get a free copy of the StockNews.com research report on BELLUS Health (BLU)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Are Baidu’s Delisting Fears a Good Entry for New Investors?
- 3 Earnings Announcements That Could Surprise
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.